VAR2CSA antibodies and methods of use thereof

Abstract

The present disclosure relates to compositions and methods for treating and / or preventing malarial infections. In some embodiments, the present disclosure provides recombinant antibodies and compositions thereof for treating and / or preventing a malarial infection. The present disclosure also provides methods of using the recombinant antibodies and compositions thereof to treat and / or prevent a malarial infection.

Description

[0001] Docket No.10644-190WO1 VAR2CSA ANTIBODIES AND METHODS OF USE THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to, and the benefit of, U.S. Provisional Patent Application No.63 / 636,205, filed April 19, 2024, which is incorporated by reference herein in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with Government Support under Grant No. R21AI164147-01 awarded by the National Institutes of Health. The Government has certain rights in the invention. REFERENCE TO SEQUENCE LISTING The sequence listing submitted on April 19, 2025, as an .XML file entitled “10644- 190WO1 – VAR2CSA ANTIBODIES” created on April 3, 2025, and having a file size of 15,307,114 bytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5). FIELD The present disclosure relates to compositions and methods for treating and / or preventing malarial infections. BACKGROUND Monoclonal antibody therapeutics have become a mainstay in treatment options for a variety of human diseases such as infection, cancer and autoimmunity due to their high target specificity and relatively low incidence of adverse effects. Recently, monoclonal antibodies have attracted attention as an additional tool to treat and / or prevent infection with malaria parasites. Although there are effective drugs used to treat infection (artemisinin combined therapies), the lack of a fully protective licensed malaria vaccine and the emergence of resistance to current drug regimens underscore the need for improved antibody treatments. The compounds, compositions, and methods disclosed herein address these and other needs. Docket No.10644-190WO1 SUMMARY The present disclosure provides recombinant antibodies and compositions thereof for treating and / or preventing a malarial infection. The present disclosure also provides methods of using the recombinant antibodies and compositions thereof to treat and / or prevent a malarial infection. In some aspects, disclosed herein is arecombinant antibody comprising a light chainvariable (VL) region and a heavy chain variable (VH) region, wherein the VLand VHcomprisean antigen binding site targeting at least oneVAR2CSA antigen, or a variant thereof.In some aspects, disclosed herein is a therapeutic composition comprising a recombinant antibody comprising a light chain variable (VL) region and a heavy chain variable (VH) region, wherein the VLand VHcomprise an antigen binding site targeting at least oneVAR2CSA antigen,or a variant thereof; and a pharmaceutically acceptable carrier. In some embodiments, the antigen binding site targets 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants. In some embodiments, theVL comprises a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, theVH comprises a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, theVL comprises a complementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, or an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. Docket No.10644-190WO1 In some embodiments, theVH comprises a complementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 or SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, theVL comprises a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, theVH comprises a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. In some embodiments, the recombinant antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3 selected from the group consisting of SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI; SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS; Docket No.10644-190WO1 SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS; SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD; SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS; SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR; SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA; SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE; SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT; SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS; SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS; SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS; SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS; SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS; SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS; SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS; SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN; SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: Docket No.10644-190WO1 11464, and amino acid sequence ENN; SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS; SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI; SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS; SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS; SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS; SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS; SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT; SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS; SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS; SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI; SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS; SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN; SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS; Docket No.10644-190WO1 SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS; SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS; SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS; SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS; SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS; SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS; SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK; SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT; SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS; SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT; SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS; and SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the VAR2CSA antigen is expressed in a Plasmodium falciparum (P. falciparum) parasite. In some embodiments, the recombinant antibody is a monoclonal antibody. In some embodiments, the recombinant antibody is an adhesion inhibitory antibody. In some embodiments, the therapeutic composition of any preceding aspect further comprises an adjuvant, an additive, a preservative, or any combination thereof. In some embodiments, the therapeutic composition of any preceding aspect comprises a vaccine. In some embodiments, the pharmaceutically acceptable carrier comprises an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof. In some aspects, disclosed herein is a nucleic acid encoding the recombinant antibody of any preceding aspect. In some aspects, disclosed herein is an expression vector comprising the nucleic acid of any preceding aspect. In some aspects, disclosed herein is a cell comprising the nucleic acid of any preceding aspect or the expression vector of any preceding aspect. Docket No.10644-190WO1 In some aspects, disclosed herein is a method of treating or preventing a malaria infection in a subject in need thereof, the method comprising administering a recombinantantibody or a composition comprising the recombinantantibody, wherein the recombinantantibody comprises a light chain variable (VL) region and a heavy chain variable (VH) region, and wherein the VLand VHcomprise an antigen binding sitetargeting at least oneVAR2CSA antigen, or a variant thereof. In some embodiments, the method of treating or preventing comprises the antigen binding site targeting 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants. In some embodiments, the method of treating of preventing comprises theVL comprising a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, the method of treating or preventing comprises theVH comprising a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, the method of treating or preventing comprises theVL comprises a complementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, and an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. In some embodiments, the method of treating or preventing comprises theVH comprising a complementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 and SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, the method of treating or preventing comprises theVL comprises a complementarity determining region (CDR) 1 comprising a sequence selected Docket No.10644-190WO1 from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, the method of treating or preventing comprises theVH comprises a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. In some embodiments, the malaria is a placental malaria. In some embodiments, the malaria is caused by a Plasmodium falciparum (P. falciparum) infection. In some embodiments, the VAR2CSA antigen is expressed in a P. falciparum parasite. In some embodiments, the method of treating or preventing comprises the recombinant antibody being a monoclonal antibody. In some embodiments, the method of treating or preventing comprises the recombinant antibody is an adhesion inhibitory antibody. In some embodiments, the method of treating or preventing comprises the recombinant antibody of any preceding aspect or the therapeutic composition of any preceding aspect further comprising an adjuvant, an additive, a preservative, or any combination thereof. In some embodiments, the method of treating or preventing comprises the recombinant antibody of any preceding aspect or the therapeutic composition of any preceding aspect further comprising a pharmaceutically acceptable carrier comprising an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof. In some embodiments, the method of Docket No.10644-190WO1 treating or preventing comprises the therapeutic composition comprises being a vaccine. In some embodiments, the recombinant antibody of any preceding aspect prevents the VAR2CSA antigen from binding to a chondroitin sulphate A (CSA) receptor. In some embodiments, the CSA receptor is expressed in the subject. BRIEF DESCRIPTION OF FIGURES The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects described below. FIGS.1A, 1B, and 1C show that PM / VAR2CSA leads to naturally acquired immunity (NAI). Serum from exposed women have higher levels of antibodies targeting VAR2CSA and higher levels of adhesion inhibitory antibodies. The capacity of anti-VAR2CSA antibodies to block the adhesion of IEs to CSA is thought to play a major role in protection. FIG.2 shows that VAR2CSA is a vaccine candidate. FIGS. 3A, 3B, and 3C show VAR2CSA sequence diversity and how the subunit VAR2CSA-vaccine candidate do not display all the epitopes involved in CSA binding and is mostly recognized by mono-reactive antibodies. FIG. 4 shows that Linking B Cell Receptor to Antigen specificity through Sequencing (LIBRA-seq) is used to discover VAR2CSA-specific monoclonal antibodies (mAbs). LIBRA- seq allows for simultaneous recovery of B cell receptors (BCRs) / mAbs sequence and antigen specificity. FIG. 5 shows the use of LIBRA-seq with ligand blocking (using full-length (FL) VAR2CSA and its receptor CSA) to identify VAR2CSA-specific mAbs, especially those with adhesion-blocking capacity. FIGS. 6A and 6B show the seven VAR2CSA variants chosen to perform LIBRA-seq with ligand blocking. FIGS. 7A and 7B show that LIBRA-seq was used to identify 987 VAR2CSA specific mAbs in total, wherein 86% were cross-reactive. FIGS.8A and 8B show that cross-reactivity correlates with adhesion blocking capacity, wherein 45% of mAbs block VAR2CSA adhesion to CSA. FIGS. 9A and 9B show that cross-reactivity is not correlated with somatic hypermutation (SHM) levels. FIGS.10A, 10B, and 10C show the validation of a sub-set of 50 lead candidates mAbs confirming they bind to recombinant VAR2CSA (as FL recombinant antigen and / or as shorter Docket No.10644-190WO1 regions: ID1-ID2, DBL3x and DBL5ε). They also binding to native VAR2CSA expressed on the surface of Plasmodium falciparum infected erythrocytes (IEs) DETAILED DESCRIPTION The following description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known embodiment(s). To this end, those skilled in the relevant art will recognize and appreciate that many changes can be made to the various embodiments of the invention described herein, while still obtaining the beneficial results of the present disclosure. It will also be apparent that some of the desired benefits of the present disclosure can be obtained by selecting some of the features of the present disclosure without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the present disclosure are possible and can even be desirable in certain circumstances and are a part of the present disclosure. Thus, the following description is provided as illustrative of the principles of the present disclosure and not in limitation thereof. Reference will now be made in detail to the embodiments of the invention, examples of which are illustrated in the drawings and the examples. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Terminology Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments and are also disclosed. As used in this disclosure and in the appended claims, the singular forms “a”, “an”, “the”, include plural referents unless the context clearly dictates otherwise. The following definitions are provided for the full understanding of terms used in this specification. Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, another embodiment includes from Docket No.10644-190WO1 the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed the “less than or equal to 10”as well as “greater than or equal to 10” is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed. The terms "about" and "approximately" are defined as being “close to” as understood by one of ordinary skill in the art. In one non-limiting embodiment the terms are defined to be within 10%. In another non-limiting embodiment, the terms are defined to be within 5%. In still another non-limiting embodiment, the terms are defined to be within 1%. As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation "may include an excipient" is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient. “Composition” refers to any agent that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, e.g., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, e.g., prevention of a disorder or other undesirable physiological condition. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, a vector, polynucleotide, cells, salts, esters, amides, Docket No.10644-190WO1 proagents, active metabolites, isomers, fragments, analogs, and the like. When the term “composition” is used, then, or when a particular composition is specifically identified, it is to be understood that the term includes the composition per se as well as pharmaceutically acceptable, pharmacologically active vector, polynucleotide, salts, esters, amides, proagents, conjugates, active metabolites, isomers, fragments, analogs, etc. "Comprising" is intended to mean that the compositions, methods, etc. include the recited elements, but do not exclude others. "Consisting essentially of'' when used to define compositions and methods, shall mean including the recited elements, but excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of'' shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions provided and / or claimed in this disclosure. Embodiments defined by each of these transition terms are within the scope of this disclosure. An "increase" can refer to any change that results in a greater amount of a symptom, disease, composition, condition, or activity. An increase can be any individual, median, or average increase in a condition, symptom, activity, composition in a statistically significant amount. Thus, the increase can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100% or more increase so long as the increase is statistically significant. A "decrease" can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity. A substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance. Also, for example, a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed. A decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount. Thus, the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100%, or more decrease so long as the decrease is statistically significant. "Inhibit," "inhibiting," and "inhibition" mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for Docket No.10644-190WO1 example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction below, above, or in between the given ranges as compared to native or control levels. By “reduce” or other forms of the word, such as “reducing” or “reduction,” means lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. By “prevent” or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed. The terms “treat,” “treating,” and grammatical variations thereof as used herein, include partially or completely delaying, alleviating, mitigating or reducing the intensity of one or more attendant symptoms of a disorder or condition and / or alleviating, mitigating or impeding one or more causes of a disorder or condition. Treatments according to the disclosure may be applied preventively, prophylactically, palliatively or remedially. Treatments are administered to a subject prior to onset (e.g., before obvious signs of infection), during early onset (e.g., upon initial signs and symptoms of a parasitic infection, such as for example, a malarial infection), or after an established development of a parasitic infection, such as for example, a malarial infection. The term “subject” refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. In one aspect, the subject can be human, non-human primate, bovine, equine, porcine, canine, or feline. The subject can also be a guinea pig, rat, hamster, rabbit, mouse, or mole. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician. Docket No.10644-190WO1 The term “therapeutically effective amount” refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination. The term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. The term “administer,” “administering”, or derivatives thereof refer to delivering a composition, substance, inhibitor, or medication to a subject or object by one or more the following routes: oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation or via an implanted reservoir. The term “parenteral” includes subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injections or infusion techniques. Reference also is made herein to peptides, polypeptides, proteins, and compositions comprising peptides, polypeptides, and proteins. As used herein, a polypeptide and / or protein is defined as a polymer of amino acids, typically of length≥100 amino acids (Garrett & Grisham, Biochemistry, 2nd edition, 1999, Brooks / Cole, 110). A peptide is defined as a short polymer of amino acids, of a length typically of 20 or less amino acids, and more typically of a length of 12 or less amino acids (Garrett & Grisham, Biochemistry, 2nd edition, 1999, Brooks / Cole, 110). The term “amino acid,” includes but is not limited to amino acids contained in the group consisting of alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile Docket No.10644-190WO1 or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W), and tyrosine (Tyr or Y) residues. The term “amino acid residue” also may include amino acid residues contained in the group consisting of homocysteine, 2-Aminoadipic acid, N-Ethylasparagine, 3-Aminoadipic acid, Hydroxylysine, β-alanine, β-Amino-propionic acid, allo-Hydroxylysine acid, 2-Aminobutyric acid, 3-Hydroxyproline, 4-Aminobutyric acid, 4-Hydroxyproline, piperidinic acid, 6- Aminocaproic acid, Isodesmosine, 2-Aminoheptanoic acid, allo-Isoleucine, 2- Aminoisobutyric acid, N-Methylglycine, sarcosine, 3-Aminoisobutyric acid, N- Methylisoleucine, 2-Aminopimelic acid, 6-N-Methyllysine, 2,4-Diaminobutyric acid, N- Methylvaline, Desmosine, Norvaline, 2,2′-Diaminopimelic acid, Norleucine, 2,3- Diaminopropionic acid, Ornithine, and N-Ethylglycine. Typically, the amide linkages of the peptides are formed from an amino group of the backbone of one amino acid and a carboxyl group of the backbone of another amino acid. The peptides, polypeptides, and proteins disclosed herein may be modified to include non-amino acid moieties. Modifications may include but are not limited to carboxylation (e.g., N-terminal carboxylation via addition of a di-carboxylic acid having 4-7 straight-chain or branched carbon atoms, such as glutaric acid, succinic acid, adipic acid, and 4,4- dimethylglutaric acid), amidation (e.g., C-terminal amidation via addition of an amide or substituted amide such as alkylamide or dialkylamide), PEGylation (e.g., N-terminal or C- terminal PEGylation via additional of polyethylene glycol), acylation (e.g., O-acylation (esters), N-acylation (amides), S-acylation (thioesters)), acetylation (e.g., the addition of an acetyl group, either at the N-terminus of the protein or at lysine residues), formylation lipoylation (e.g., attachment of a lipoate, a C8 functional group), myristoylation (e.g., attachment of myristate, a C14 saturated acid), palmitoylation (e.g., attachment of palmitate, a C16 saturated acid), alkylation (e.g., the addition of an alkyl group, such as an methyl at a lysine or arginine residue), isoprenylation or prenylation (e.g., the addition of an isoprenoid group such as farnesol or geranylgeraniol), amidation at C-terminus, glycosylation (e.g., the addition of a glycosyl group to either asparagine, hydroxylysine, serine, or threonine, resulting in a glycoprotein). Distinct from glycation, which is regarded as a nonenzymatic attachment of sugars, polysialylation (e.g., the addition of polysialic acid), glypiation (e.g., glycosylphosphatidylinositol (GPI) anchor formation, hydroxylation, iodination (e.g., of thyroid hormones), and phosphorylation (e.g., the addition of a phosphate group, usually to Docket No.10644-190WO1 serine, tyrosine, threonine, or histidine). The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods consider conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide. Percent identity for amino acid sequences may be determined as understood in the art. (See, e.g., U.S. Pat. No.7,396,664, which is incorporated herein by reference in its entirety). A suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol.215:403410), which is available from several sources, including the NCBI, Bethesda, Md., at its website. The BLAST software suite includes various sequence analysis programs including “blastp,” that is used to align a known amino acid sequence with other amino acids sequences from a variety of databases. Percent identity may be measured over the length of an entire defined polypeptide sequence or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length may be used to describe a length over which percentage identity may be measured. The term “variant” means a polypeptide derived from a parent polypeptide by one or more (several) alteration(s), i.e., a substitution, insertion, and / or deletion, at one or more (several) positions. A substitution means a replacement of an amino acid occupying a position with a different amino acid; a deletion means removal of an amino acid occupying a position; and an insertion means adding 1 or more, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1-3 amino acids immediately adjacent an amino acid occupying a position. In relation to substitutions, ‘immediately adjacent’ may be to the N-side (‘upstream’) or C-side (‘downstream’) of the amino acid occupying a position (‘the named amino acid’). Therefore, for an amino acid named / numbered ‘X,’ the insertion may be at position ‘X+1’ (‘downstream’) or at position ‘X−1’ (‘upstream’). A “variant” of a particular polypeptide sequence may be defined as a polypeptide sequence having at least 50% sequence identity to the particular polypeptide sequence over a Docket No.10644-190WO1 certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool available at the National Center for Biotechnology Information's website. (See Tatiana A. Tatusova, Thomas L. Madden (1999), “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol Lett. 174:247-250). In some embodiments a variant polypeptide may show, for example, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length relative to a reference polypeptide. A variant polypeptide may have substantially the same functional activity as a reference polypeptide. For example, a variant polypeptide may exhibit or more biological activities associated with binding a ligand and / or binding DNA at a specific binding site. Variants comprising a fragment of a reference amino acid sequence are contemplated herein. A “fragment” is a portion of an amino acid sequence which is identical in sequence to but shorter in length than the reference sequence. A fragment may comprise up to the entire length of the reference sequence, minus at least one amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous amino acid residues of a reference polypeptide, respectively. In some embodiments, a fragment may comprise at least 5, 10, 15, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 150, 250, or 500 contiguous amino acid residues of a reference polypeptide, respectively. Fragments may be preferentially selected from certain regions of a molecule, for example the N-terminal region and / or the C- terminal region of a polypeptide. The term “at least a fragment” encompasses the full length polypeptide. The term "antibody" is used in the broadest sense, and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies). Antibodies (Abs) and immunoglobulins (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific target, immunoglobulins include both antibodies and other antibody-like molecules which lack target specificity. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end. A particular kind of chimeric antibody is a “humanized” antibody, in which the Docket No.10644-190WO1 antibodies are produced by substituting the CDRs of, for example, a mouse antibody, for the CDRs of a human antibody (see e.g., PCT International Patent Application Publication No. WO 1992 / 22653). Thus, in some embodiments, a humanized antibody has constant regions and variable regions other than the CDRs that are derived substantially or exclusively from the corresponding regions of a human antibody, and CDRs that are derived substantially or exclusively from a mammal other than a human. The term "antibody fragment" refers to a portion of a full-length antibody, generally the target binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments. The phrase "functional fragment or analog" of an antibody is a compound having qualitative biological activity in common with a full-length antibody. For example, a functional fragment or analog of an anti-IgE antibody is one which can bind to an IgE immunoglobulin in such a manner so as to prevent or substantially reduce the ability of such molecule from having the ability to bind to the high affinity receptor, FcεRI. As used herein, "functional fragment" with respect to antibodies, refers to Fv, F(ab) and F(ab')2 fragments. An "Fv" fragment is the minimum antibody fragment which contains a complete target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (VH-VLdimer). It is in this configuration that the three CDRs of each variable domain interact to define a target binding site on the surface of the VH-VLdimer. Collectively, the six CDRs confer target binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for a target) has the ability to recognize and bind target, although at a lower affinity than the entire binding site. "Single-chain Fv" or "sFv" antibody fragments comprise the VHand VLdomains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VHand VLdomains which enables the sFv to form the desired structure for target binding. The term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. A “vaccine” refers to a biological preparation that provides active acquired immunity to a particular infectious diseases caused by a virus, bacteria, parasite, or any other microorganisms. Vaccines typically comprise an agent or several agents, also referred to as antigens, resembling the disease-causing microorganism and is often made from weakened or Docket No.10644-190WO1 killed forms of the microbe, its toxins, or its surface proteins / peptides. Vaccines are also made to comprise additional components, such as adjuvants, preservatives, and / or stabilizers to boost the immune response, improve safety, and improve vaccine storage. The term "variable" in the context of variable domain of antibodies, refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular target. However, the variability is not evenly distributed through the variable domains of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) also known as hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely an adopting a .beta.-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the .beta.-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the target binding site of antibodies. As used herein, numbering of immunoglobulin amino acid residues is done according to the immunoglobulin amino acid residue numbering system of Kabat et al., (Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, Md.1987), unless otherwise indicated. A “pharmaceutically effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. "Pharmaceutically acceptable carrier" (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and / or human pharmaceutical or therapeutic use. The terms "carrier" or "pharmaceutically acceptable carrier" can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil / water or water / oil emulsion) and / or various types of wetting agents. Recombinant Antibodies and Compositions The present disclosure provides recombinant antibodies and compositions thereof for treating and / or preventing a malarial infection. Docket No.10644-190WO1 In some aspects, disclosed herein is arecombinant antibody comprising a light chainvariable (VL) region and a heavy chain variable (VH) region, wherein the VLand VHcomprisean antigen binding site targeting at least oneVAR2CSA antigen, or a variant thereof.As used herein, “recombinant antibody” refers to synthetic or genetically engineered antibodies or antibody fragment using recombinant DNA technology. The process of producing recombinant antibodies includes cloning antibody genes, including the engineered complementarity determining regions (CDRs), heavy chain, and light chain, into expression vectors, which are then introduced into host cells (such as for example bacteria, yeast cells, insect cells, or mammalian cells) to produce the desired antibody, or fragment thereof. Plasmodium falciparum (P. falciparum) malaria is one of the leading causes of human malaria in the world. The adhesion of infected erythrocytes to vascular endothelium or placenta is the key event in pathogenesis of P. falciparum infection. In pregnant women, the P. falciparum parasite express an erythrocyte membrane protein called VAR2CSA, which is associated with the ability of infected erythrocytes to adhere specifically to chondroitin sulphate (CSA) in the placenta. VAR2CSA is a large 350 kDa protein comprising of six Duffy- binding-like (DBL) domains and three larger interdomain regions. Antibodies to the surface- expressed VAR2CSA protein are acquired by women who are exposed to malaria during pregnancy, and high levels of anti-VAR2CSA antibodies at delivery are associated with protection from low-birth-weight babies, one of the major complications of pregnancy- associated malaria (PAM). Antibodies targeting VAR2CSA presumably abrogate or prevent binding to the vascular bed and thus protect against the adverse effects of the disease. Although VAR2CSA is a recognized malaria vaccine candidate, there is a lack of a fully protective licensed malaria vaccine to prevent or treat malaria infection in any subject, including but not limited to pregnant women. In some aspects, disclosed herein is a therapeutic composition comprising arecombinant antibody comprisinga light chain variable (VL) region and a heavy chain variable (VH) region, wherein the VLand VHcomprise an antigen binding site targeting at least oneVAR2CSA antigen,or a variant thereof; and a pharmaceutically acceptable carrier. As used herein, an “antigen-binding site”, also known as a “paratope”, refers to the region within the antibody, or a fragment thereof, where the antibody specifically recognizes and binds to a particular antigen, wherein said site is formed by the variable regions of both the heavy and light chains. Docket No.10644-190WO1 In some embodiments, the antigen binding site targets 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants. In some embodiments, the antigen binding site targets one VAR2CSA variant. In some embodiments, the antigen binding site targets two VAR2CSA variants. In some embodiments, the antigen binding site targets three VAR2CSA variants. In some embodiments, the antigen binding site targets four VAR2CSA variants. In some embodiments, the antigen binding site targets five VAR2CSA variants. In some embodiments, the antigen binding site targets six VAR2CSA variants. In some embodiments, the antigen binding site targets seven VAR2CSA variants. In some embodiments, theVL comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, theVL comprises a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, the VH comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, theVH comprises a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, the VL comprises a complementarity determining region comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 10767 – SEQ ID NO: 12254, or an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. Docket No.10644-190WO1 In some embodiments, theVL comprises a complementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, or an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. In some embodiments, theVH comprises a complementarity determining region comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 or at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, theVH comprises a complementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 or SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, theVL comprises a complementarity determining region (CDR) 1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, Docket No.10644-190WO1 DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, theVL comprises a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, theVH comprises a CDR1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. Docket No.10644-190WO1 In some embodiments, theVH comprises a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. In some embodiments, the recombinant antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3 selected from the group consisting of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI; SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS; SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS; SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD; SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS; SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR; SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA; SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE; SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT; SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS; SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS; Docket No.10644-190WO1 SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS; SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS; SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS; SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS; SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS; SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN; SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN; SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS; SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI; SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS; SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS; SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS; SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS; SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT; SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS; SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: Docket No.10644-190WO1 11536, and amino acid sequence AAS; SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI; SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS; SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN; SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS; SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS; SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS; SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS; SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS; SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS; SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS; SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK; Docket No.10644-190WO1 SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT; SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS; SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT; SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS; and SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3 selected from the group consisting of SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI; SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS; SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS; SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD; SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS; SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR; SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA; SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE; SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: Docket No.10644-190WO1 11422, and amino acid sequence QDT; SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS; SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS; SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS; SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS; SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS; SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS; SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS; SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN; SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN; SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS; SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI; SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS; SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS; SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS; SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS; Docket No.10644-190WO1 SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT; SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS; SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS; SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI; SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS; SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN; SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS; SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS; SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS; SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS; SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS; SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID Docket No.10644-190WO1 NO: 11684, and amino acid sequence KAS; SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS; SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK; SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT; SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS; SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT; SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS; and SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID Docket No.10644-190WO1 NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK. Docket No.10644-190WO1 In some embodiments, the recombinant antibody comprises SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS. In some embodiments, the recombinant antibody comprises SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS. In some embodiments, the VAR2CSA antigen is expressed in a Plasmodium falciparum (P. falciparum) parasite. In some embodiments, the recombinant antibody is a monoclonal antibody. In some embodiments, the recombinant antibody is an adhesion inhibitory antibody. As used herein, an “adhesion inhibitory antibody” refers to a type of antibody that specifically targets and blocks the binding of adhesion molecules, thereby preventing cells from adhering to each other or to the extracellular matrix, which can have implications in various biological processes, including but not limited to metastasis and inflammation. In some embodiments, the therapeutic composition of any preceding aspect further comprises an adjuvant, an additive, a preservative, or any combination thereof. In some embodiments, the therapeutic compositions of any preceding aspect comprises an adjuvant including but not limited to aluminum salts, emulsion adjuvants (such as for example MF59 and AS03), synthetic DNA-like molecules (such as for example CpGs), monophosphoryl lipid A (MPL), QS21, TLR agonist molecule-based adjuvants (such as for example AS04 and CpG ODN 1018), Matrix-MTM, polymeric adjuvants, saponins, or a combination thereof. In some embodiments, the therapeutic compositions of any preceding aspect comprise an additive including but not limited to stabilizers (such as for example sugars, gelatin, and polysorbate 80) and trace materials (such as for example cell culture materials, antibiotics, and Docket No.10644-190WO1 formaldehyde). In some embodiments, the therapeutic compositions of any preceding aspect comprise a preservative including but not limited to thimerosal, formaldehyde, and antibiotics. In some embodiments, the therapeutic composition of any preceding aspect comprises a vaccine. In some embodiments, the pharmaceutically acceptable carrier comprises an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof. Vectors In some aspects, disclosed herein is a nucleic acid encoding the recombinant antibody of any preceding aspect. In some embodiments, the nucleic acid comprises a heavy chain nucleic acid sequence comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequences selected from SEQ ID NO: 1 – SEQ ID NO: 981. In some embodiments, the nucleic acid comprises a heavy chain nucleic acid sequence selected from SEQ ID NO: 1 – SEQ ID NO: 981. In some embodiments, the heavy chain nucleic acid sequence comprises a complementarity determining region (CDR) comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 982 – SEQ ID NO: 3529. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 982 – SEQ ID NO: 1777. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from 1778 – SEQ ID NO: 2559. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR3 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 2560 – 3529. In some embodiments, the heavy chain nucleic acid sequence comprises a complementarity determining region (CDR) sequence selected from SEQ ID NO: 982 – SEQ ID NO: 3529. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR1 sequence selected from SEQ ID NO: 982 – SEQ ID NO: 1777. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR2 sequence selected from 1778 – SEQ ID NO: 2559. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR3 sequence selected from SEQ ID NO: 2560 – 3529. Docket No.10644-190WO1 In some embodiments, the nucleic acid comprises a light chain nucleic acid comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 3530 – SEQ ID NO: 4509. In some embodiments, the nucleic acid comprises a light chain nucleic acid sequence selected from SEQ ID NO: 3530 – SEQ ID NO: 4509. In some embodiments, the heavy chain nucleic acid sequence comprises a complementarity determining region (CDR) comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 4510 – SEQ ID NO: 6526. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 4510 - SEQ ID NO: 5239. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 5240 – SEQ ID NO: 5580. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR3 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the sequence selected from SEQ ID NO: 5581 – SEQ ID NO: 6526. In some embodiments, the heavy chain nucleic acid sequence comprises a complementarity determining region (CDR) sequence selected from SEQ ID NO: 4510 – SEQ ID NO: 6526. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR1 sequence selected from SEQ ID NO: 4510 - SEQ ID NO: 5239. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR2 sequence selected from SEQ ID NO: 5240 – SEQ ID NO: 5580. In some embodiments, the heavy chain nucleic acid sequence comprises a CDR3 sequence selected from SEQ ID NO: 5581 – SEQ ID NO: 6526. In some aspects, disclosed herein is an expression vector comprising the nucleic acid of any preceding aspect. In some embodiments, the expression vector comprises a plasmid or a virus or viral vector. A plasmid or a viral vector can be capable of extrachromosomal replication or, optionally, can integrate into the host genome. As used herein, the term "integrated" used in reference to an expression vector (e.g., a plasmid or viral vector) means the expression vector, or a portion thereof, is incorporated (physically inserted or ligated) into the chromosomal DNA of a host cell. As used herein, a “viral vector” refers to a virus-like particle containing genetic material which can be introduced into a eukaryotic cell without causing substantial pathogenic Docket No.10644-190WO1 effects to the eukaryotic cell. A wide range of viruses or viral vectors can be used for transduction but should be compatible with the cell type the virus or viral vector are transduced into (e.g., low toxicity, capability to enter cells). Suitable viruses and viral vectors include adenovirus, lentivirus, retrovirus, among others. Retroviral Vectors A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, I.M., Retroviral vectors for gene transfer. A retrovirus is essentially a package which has packed into it nucleic acid cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert. Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new Docket No.10644-190WO1 retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals. Adenoviral Vectors The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol.6:2872-2883 (1986); Haj- Ahmad et al., J. Virology 57:267-274 (1986); Davidson et al., J. Virology 61:1226-1239 (1987); Zhang "Generation and identification of recombinant adenovirus by liposome- mediated transfection and PCR analysis" BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993); Roessler, J. Clin. Invest. 92:1085-1092 (1993); Moullier, Nature Genetics 4:154-159 (1993); La Salle, Science 259:988-990 (1993); Gomez-Foix, J. Biol. Chem. 267:25129-25134 (1992); Rich, Human Gene Therapy 4:461-476 (1993); Zabner, Nature Genetics 6:75-83 (1994); Guzman, Circulation Research 73:1201-1207 (1993); Bout, Human Gene Therapy 5:3-10 (1994); Zabner, Cell 75:207-216 (1993); Caillaud, Eur. J. Neuroscience 5:1287-1291 (1993); and Ragot, J. Gen. Virology 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenovirus (Chardonnet and Dales, Virology 40:462-477 (1970); Brown and Burlingham, J. Virology 12:386-396 (1973); Svensson and Persson, J. Virology 55:442-449 (1985); Seth, et al., J. Virol. 51:650-655 (1984); Seth, et al., Mol. Cell. Biol. 4:1528-1533 (1984); Varga et al., J. Virology 65:6061-6070 (1991); Wickham et al., Cell 73:309-319 (1993)). A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virons are generated in a cell line such as the human 293 cell line. In another preferred embodiment both the E1 and E3 genes are removed from the adenovirus genome. Adeno-asscociated viral vectors Another type of viral vector is based on an adeno-associated virus (AAV). This defective parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV Docket No.10644-190WO1 is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the herpes simplex virus thymidine kinase gene, HSV-tk, and / or a marker gene, such as the gene encoding the green fluorescent protein, GFP. In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus. Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site- specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. United states Patent No. 6,261,834 is herein incorporated by reference for material related to the AAV vector. Large payload viral vectors Molecular genetic experiments with large human herpesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpesviruses (Sun et al., Nature genetics 8: 33-41, 1994; Cotter and Robertson,.Curr Opin Mol Ther 5: 633-644, 1999). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable The maintenance of these episomes requires a specific EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro. Herpesvirus amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes. In some embodiments, the expression vector encoding the recombinant antibody is a naked DNA or is comprised in a nanoparticle. Other useful systems include, for example, replicating and host-restricted non- replicating vaccinia virus vectors. In some aspects, disclosed herein is a cell comprising the nucleic acid of any preceding Docket No.10644-190WO1 aspect. In some aspects, disclosed herein is a cell comprising the expression vector of any preceding aspect. In some embodiments, the cell of any preceding aspect comprises a host cell selected from a bacterial cell, a yeast cell, an insect cell, or a mammalian cell. In some embodiments, the bacterial cell is derived from a bacterium including but not limited to Escherichia coli (E. coli). In some embodiments, the yeast cell is derived from a yeast selected from Saccharomyoces cerevisiae (S. cerevisiae). In some embodiments, the insect cell includes but is not limited to SF9 and SF21 insect cells. In some embodiments, the mammalian cell includes but is not limited to a human embryonic kidney (HEK) cell, a Chinese hamster ovarian (CHO) cell, a HeLa cell, or any variants thereof. Methods of treating or preventing a malarial infection Malaria is a mosquito-borne disease that can be prevented using vaccinations. However, current malaria vaccines are not effective against all variations of malaria. The present disclosure provides recombinant antibodies, or compositions thereof that prevent infection from several malaria variants. The present disclosure also provides methods of using the recombinant antibodies and compositions thereof to treat and / or prevent a malarial infection. In some aspects, disclosed herein is a method of treating or preventing malaria in a subject in need thereof, the method comprising administering a recombinant antibody or acomposition comprising the recombinantantibody, wherein the recombinant antibodycomprises a light chain variable (VL) region and a heavy chain variable (VH) region, and wherein the VL and VH comprise an antigen binding site targeting at least one VAR2CSA antigen, or a variant thereof. In some aspect, disclosed herein is a method of treating or preventing malaria in a subject in need thereof, the method comprising administering the recombinant antibody or a therapeutic composition thereof of any preceding aspect. In some embodiments, the method of treating or preventing comprises the antigen binding site targeting 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants. In some embodiments, the antigen binding site targets one VAR2CSA variant. In some embodiments, the antigen binding site targets two VAR2CSA variants. In some embodiments, the antigen binding site targets three VAR2CSA variants. In some embodiments, the antigen binding site targets four VAR2CSA Docket No.10644-190WO1 variants. In some embodiments, the antigen binding site targets five VAR2CSA variants. In some embodiments, the antigen binding site targets six VAR2CSA variants. In some embodiments, the antigen binding site targets seven VAR2CSA variants. In some embodiments, the method of treating or preventing comprises theVL comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, the method of treating or preventing comprises theVH comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, the method of treating or preventing comprises theVL comprising a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356. In some embodiments, the method of treating or preventing comprises theVH comprising a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305. In some embodiments, the method of treating or preventing comprises a light chain complementarity determining region (CDR) comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 10767 – SEQ ID NO: 12254, and an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. In some embodiments, the method of treating or preventing comprises a light chain complementarity determining region (CDR) selected from SEQ ID NO: 7483 – SEQ ID NO: Docket No.10644-190WO1 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, and an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT. In some embodiments, the method of treating or preventing comprises a heavy chain complementarity determining region (CDR) comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 and SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, the method of treating or preventing comprises a heavy chain complementarity determining region (CDR) comprising a sequence selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 and SEQ ID NO: 8375 – SEQ ID NO: 10766. In some embodiments, the method of treating or preventing comprises theVL comprises a complementarity determining region (CDR) 1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, Docket No.10644-190WO1 AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, the method of treating or preventing comprises theVL comprises a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254. In some embodiments, the method of treating or preventing comprises the VH comprises a CDR1 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. In some embodiments, the method of treating or preventing comprises theVH Docket No.10644-190WO1 comprises a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766. In some embodiments, the malaria is a placental malaria. In some embodiments, the malaria is caused by a Plasmodium falciparum (P. falciparum) infection. In some embodiments, the VAR2CSA antigen is expressed in a P. falciparum parasite. In some embodiments, the method of treating or preventing comprises the recombinant antibody being a monoclonal antibody. In some embodiments, the method of treating or preventing comprises the recombinant antibody is an adhesion inhibitory antibody. In some embodiments, the method of treating or preventing comprises the recombinant antibody of any preceding aspect or the therapeutic composition of any preceding aspect further comprises an adjuvant, an additive, a preservative, or any combination thereof. In some embodiments, the method of treating or preventing comprises the recombinant antibody of any preceding aspect or the therapeutic composition of any preceding aspect further comprising a pharmaceutically acceptable carrier comprising an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof. In some embodiments, the method of treating or preventing comprises the therapeutic composition comprises being a vaccine. The therapeutic compositions of any preceding aspect may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result. The exact amount of the therapeutic compositions of any preceding aspect will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular therapeutic compositions of any preceding aspect, its mode of administration, its mode of activity, and the like. The therapeutic compositions of any preceding aspect is preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the therapeutic compositions of any preceding aspect will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the malarial infection being treated and the severity of the infection; the activity of the therapeutic compositions of any preceding aspect employed; the specific therapeutic compositions of any preceding aspect employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific therapeutic compositions of any preceding aspect employed; the duration of the treatment; drugs used in Docket No.10644-190WO1 combination or coincidental with the specific therapeutic composition of any preceding aspect employed; and like factors well known in the medical arts. The therapeutic composition of any preceding aspect may be administered by any route. In some embodiments, the therapeutic compositions of any preceding aspect is administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and / or drops), mucosal, nasal, buccal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or as an oral spray, nasal spray, and / or aerosol. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the therapeutic composition of any preceding aspect (e.g., its stability in the environment of the blood stream), the condition of the subject (e.g., whether the subject is able to tolerate administration), etc. The exact amount of therapeutic composition of any preceding aspect required to achieve a therapeutically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects, identity of the particular compound(s), mode of administration, and the like. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. In one aspect, disclosed herein is therapeutic composition of any preceding aspect and a pharmaceutically acceptable carrier selected from an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, and a cream. One or more active agents (e.g. the anti-VAR2CSA antibody) can be administered in the “native” form or, if desired in the form of salts, esters, amides, prodrugs, or a derivative that is pharmacologically suitable. Salts, esters, amides, prodrugs, and other derivatives of the active agents can be prepared using standards procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by March (1992) Advanced Organic Chemistry; Reactions, Mechanisms, and Structure, 4thEd. N.Y. Wiley-Interscience. In some embodiments, the therapeutic composition of any preceding aspect is administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, Docket No.10644-190WO1 100, or more times. In some embodiments, the therapeutic composition of any preceding aspect is administered every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, every 12 months, or more. In some embodiments, the therapeutic composition of any preceding aspect is administered every year, every 2 years, every 3 years, every 4 years, every 5 years, or more. In some embodiments, the therapeutic composition or the recombinant antibody of any preceding aspect can be administered in combination with an antimalarial drug including, but not limited to chloroquine phosphate, Artemisinin-based combination therapies (ACTs), Atovaquone-proquanil (Malarone), Quinine sulfate (Qualaquin) in combination with an antibiotic (such as for example doxycycline), and Primaquine phosphate. In some embodiments, the therapeutic composition or the recombinant antibody of any preceding aspect can be administered simultaneously or concurrently with the antimalarial drug. In some embodiments, the therapeutic composition or the recombinant antibody of any preceding aspect can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or more days before administration of the antimalarial drug. In some embodiments, the therapeutic composition or the recombinant antibody of any preceding aspect can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more days after administration of the antimalarial drug. In some embodiments, the recombinant antibody of any preceding aspect prevents the VAR2CSA antigen from binding to a chondroitin sulphate A (CSA) receptor. In some embodiments, the CSA receptor is expressed in the subject. A number of embodiments of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. Docket No.10644-190WO1 By way of non-limiting illustration, examples of certain embodiments of the present disclosure are given below. EXAMPLES The following examples are set forth below to illustrate the compositions, devices, methods, and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art. Example 1: High-throughput isolation of cross-reactive and adhesion-inhibitory VAR2CSA-specific monoclonal antibodies from Plasmodium falciparum-exposed pregnant women. Placental Plasmodium falciparum malaria (PM) is a severe complication in pregnancy in areas with stable parasite transmission. PM mainly affects primigravidae, as immunity is developed over subsequent pregnancies. Naturally acquired immunity (NAI) against PM is mediated by IgG antibodies targeting a parasite antigen called VAR2CSA, a member of the parasite-derived P. falciparum erythrocyte membrane protein 1 (PfEMP1) family with the ability to bind the host cell receptor chondroitin sulphate A (CSA) exclusively expressed in the placenta. Protection has been correlated with the ability of VAR2CSA-specific antibodies to block adhesion and placental sequestration of infected erythrocytes. Although VAR2CSA is a variable antigen, it has been previously demonstrated that sera from multigravidae women can recognize multiple VAR2CSA variants. However, it is not clear if the acquisition of broadly cross-reactive monoclonal antibodies (mAbs) is rare and / or if protection relies on the accumulation of a broad repertoire of variant-specific mAbs, which together cover the entire repertoire of VAR2CSA variation. To address this, the antigen specificity and sequence characteristics of VAR2CSA- specific antibodies generated during natural infection was studied in detail. Specifically, B cells were collected from Ghanaian women with NAI against PM, and then isolated B cells producing antibodies reacting with a panel of seven full-length recombinant VAR2CSA variants. LIBRA-seq technology (linking B cell receptor to antigen specificity through sequencing) was used with ligand blocking, to simultaneously identify antigen specificity and degree of cross-reactivity together with the sequence of each B cell receptor (BCR) and Docket No.10644-190WO1 therefore the mAb expressed by these cells. The use of ligand blocking (LIBRA-seq in the presence of CSA) enabled the identification of mAbs with the ability to block VAR2CSA binding to CSA. 987 VAR2CSA-specific mAbs were isolated, the majority (>85%) of them were cross-reactive (binding more than one of the seven VAR2CSA variants). However, pan- reactivity (defined as reactivity against all seven variants) was exceedingly rare (0.06%). When LIBRA-seq was performed in the presence of CSA, 47% of the identified mAbs were able to block binding to CSA and this functional activity correlated significantly with the levels of cross-reactivity (r=0.3, p<0.001). A subset of 50 mAbs was selected for expression as recombinant proteins and their reactivity with recombinant (by ELISA) and native VAR2CSA (by flow cytometry) was confirmed. It has been shown that naturally acquired VAR2CSA mAbs are mostly cross-reactive, yet pan-reactivity is rare. Importantly, the level of cross-reactivity correlated with the capacity of mAbs to inhibit IE adhesion, indicating that functionally relevant and protective mAbs target conserved epitopes shared by many VAR2CSA variants. This underscores the importance of the identification and characterization of such epitopes to inform current efforts towards the development of efficacious VAR2CSA-based vaccines to prevent PM. It will be apparent to those skilled in the art that various modifications and variations can be made in the present disclosure without departing from the scope or spirit of the invention. Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the methods disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

[0002] Docket No.10644-190WO1 TABLES Table 1. Heavy Chain and Light Chain Amino Acid Sequences SEQ VH SEQ ID 6 7 8 9 0 Docket No.10644-190WO1 QITLKESGPTLVKPT SSGLTQPPSVSVSPG HTLTLTCTFSGFSLTT QTATITCSGDMLGD 1 2 3 4 5 6 Docket No.10644-190WO1 DTAVYYCARCPPSTA CQAWDSSTHHYVF NDAFEIWGQGTMVT GTGTKVTVL 7 8 9 0 1 Docket No.10644-190WO1 EVQLVESGGGLVQP GRSLRLSCAASGSTF DIQMTQSPSSLSASV 2 3 4 5 6 7 Docket No.10644-190WO1 SRDDLENILYLEMTA ITGVQAEDEGDYYC LKVEDTATYYCATPP QSADTTNTYVVFGG 8 9 0 1 2 Docket No.10644-190WO1 ELQLVESGGDLVKPG GSLRLSCAAFGRKFS SYVLTQPPSVSVAP 3 4 5 6 7 8 Docket No.10644-190WO1 AEDSLYLQMTGLRV TLTISRVEAGDEAD EDTALYFCAKDMGS YYCHVWDHRSDRP 9 0 1 2 3 Docket No.10644-190WO1 EVKLVESGGDLVKP GGSLRLSCIGSGFDFS DAVVTQTPLSLSVT 4 5 6 7 8 9 Docket No.10644-190WO1 TDTSTNTAYMELRN TISSLQPDDFATYYC LRSDDTAVYYCARD QQYNSFSYTFGQGT 0 1 2 3 4 Docket No.10644-190WO1 QVQLQESGPGLVKPS QTLSITCTVSGDSIIY DVQMTQSPSSLSAS 5 6 Table 2. Heavy Chain CDRs Heavy Chain SEQ ID Heavy Chain Heavy Chain SEQ ID CDR1 NO CDR2 SEQ ID NO CDR3 NO Docket No.10644-190WO1 GASMRSGS TRDAWWYFD Docket No.10644-190WO1 AKDRGYLFQ Docket No.10644-190WO1 ARDRPFSYSR Docket No.10644-190WO1 Table 3. Light Chain CDRs Light Chain SEQ ID Light Chain SEQ ID Light Chain SEQ ID CDR1 NO CDR2 NO CDR3 NO Docket No.10644-190WO1 NIGSYS 10819 DDS - QVWDHTSDH PVV 11437 Docket No.10644-190WO1 QDISSY 11343 AAS - QQYYNYPPT 11536 Docket No.10644-190WO1 QSIGSW 10992 KAS - QQYNSFSYT 11684

Claims

Docket No.10644-190WO1 CLAIMS What is claimed is:

1. A recombinant antibody comprising a light chain variable (VL) region and a heavy chain variable (VH) region, wherein the VL and VH comprise an antigen binding site targetingat least oneVAR2CSA antigen, or a variant thereof.

2. The recombinant antibody of claim 1, wherein the antigen binding site targets 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants.

3. The recombinant antibody of claim 1 or 2, wherein theVL comprises a sequence selected from SEQ ID NO: 12306 – SEQ ID NO: 12356.

4. The recombinant antibody of any one of claims 1-3, wherein theVH comprises a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305.

5. The recombinant antibody of any one of claims 1-4, wherein the VL comprises a complementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, or an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT.Docket No.10644-190WO1 6. The recombinant antibody of any one of claims 1-5, wherein theVH comprises a complementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 or SEQ ID NO: 8375 – SEQ ID NO: 10766.

7. The recombinant antibody of any one of claims 1-6, wherein theVL comprises: a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254.

8. The recombinant antibody of any one of claims 1-7, wherein theVH comprises: a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766.

9. The recombinant antibody of any one of claims 1-8, wherein the recombinant antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3 selected from the group consisting of:Docket No.10644-190WO1 SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI; SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS; SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS; SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS; SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD; SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS; SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR; SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA; SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE; SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT; SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS; SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS; SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS; SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS; SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825, SEQ ID NO: 11446, and amino acid sequence DAS; SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO:Docket No.10644-190WO1 11447, and amino acid sequence DAS; SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS; SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN; SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN; SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS; SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI; SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS; SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS; SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS; SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS; SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT; SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS; SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS; SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI; SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS; SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS;Docket No.10644-190WO1 SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN; SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS; SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS; SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS; SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS; SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS; SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS; SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS; SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS; SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS; SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS; SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK; SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT; SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS; SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096, SEQ ID NO: 11812, and amino acid sequence DDT; SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ IDDocket No.10644-190WO1 NO: 11820, and amino acid sequence DAS; and SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS.

10. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8376, SEQ ID NO: 9080, SEQ ID NO: 9811, SEQ ID NO: 10768, SEQ ID NO: 11364, and amino acid sequence EDI.

11. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8377, SEQ ID NO: 9081, SEQ ID NO: 9812, SEQ ID NO: 10769, SEQ ID NO: 11365, and amino acid sequence DAS.

12. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9082, SEQ ID NO: 9813, SEQ ID NO: 10770, SEQ ID NO: 11366, and amino acid sequence EAS.

13. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8388, SEQ ID NO: 9092, SEQ ID NO: 9823, SEQ ID NO: 10780, SEQ ID NO: 11376, and amino acid sequence DAS.

14. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8378, SEQ ID NO: 9094, SEQ ID NO: 9825, SEQ ID NO: 10781, SEQ ID NO: 11378, and amino acid sequence EAS.

15. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8390, SEQ ID NO: 9095, SEQ ID NO: 9827, SEQ ID NO: 10783, SEQ ID NO: 11380, and amino acid sequence YDD.

16. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8397, SEQ ID NO: 9091, SEQ ID NO: 9835, SEQ ID NO: 10784, SEQ ID NO: 11388, and amino acid sequence EVS.

17. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibodyDocket No.10644-190WO1 comprises SEQ ID NO: 9078, SEQ ID NO: 9108, SEQ ID NO: 9843, SEQ ID NO: 10795, SEQ ID NO: 11396, and amino acid sequence DDR.

18. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8408, SEQ ID NO: 9112, SEQ ID NO: 9847, SEQ ID NO: 10797, SEQ ID NO: 11400, and amino acid sequence EDA.

19. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9123, SEQ ID NO: 9868, SEQ ID NO: 10810, SEQ ID NO: 11420, and amino acid sequence KNE.

20. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8421, SEQ ID NO: 9124, SEQ ID NO: 9870, SEQ ID NO: 10811, SEQ ID NO: 11422, and amino acid sequence QDT.

21. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8422, SEQ ID NO: 9125, SEQ ID NO: 9871, SEQ ID NO: 10812, SEQ ID NO: 11423, and amino acid sequence DAS.

22. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8423, SEQ ID NO: 9126, SEQ ID NO: 9873, SEQ ID NO: 10814, SEQ ID NO: 11425, and amino acid sequence DAS.

23. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8426, SEQ ID NO: 9129, SEQ ID NO: 9877, SEQ ID NO: 10772, SEQ ID NO: 11389, and amino acid sequence GAS.

24. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8391, SEQ ID NO: 9136, SEQ ID NO: 9886, SEQ ID NO: 10819, SEQ ID NO: 11437, and amino acid sequence DDS.

25. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8410, SEQ ID NO: 9142, SEQ ID NO: 9895, SEQ ID NO: 10825,Docket No.10644-190WO1 SEQ ID NO: 11446, and amino acid sequence DAS.

26. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8411, SEQ ID NO: 9143, SEQ ID NO: 9896, SEQ ID NO: 10826, SEQ ID NO: 11447, and amino acid sequence DAS.

27. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8412, SEQ ID NO: 9144, SEQ ID NO: 9897, SEQ ID NO: 10827, SEQ ID NO: 11448, and amino acid sequence LAS.

28. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8420, SEQ ID NO: 9151, SEQ ID NO: 9907, SEQ ID NO: 10837, SEQ ID NO: 11458, and amino acid sequence ENN.

29. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8425, SEQ ID NO: 9154, SEQ ID NO: 9913, SEQ ID NO: 10843, SEQ ID NO: 11464, and amino acid sequence ENN.

30. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8486, SEQ ID NO: 9184, SEQ ID NO: 9951, SEQ ID NO: 10868, SEQ ID NO: 11502, and amino acid sequence DDS.

31. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8489, SEQ ID NO: 9186, SEQ ID NO: 9955, SEQ ID NO: 10871, SEQ ID NO: 11504, and amino acid sequence KDI.

32. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8491, SEQ ID NO: 9188, SEQ ID NO: 9957, SEQ ID NO: 10873, SEQ ID NO: 11506, and amino acid sequence DDS.

33. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8497, SEQ ID NO: 9194, SEQ ID NO: 9964, SEQ ID NO: 10873, SEQ ID NO: 11514, and amino acid sequence DDS.Docket No.10644-190WO1 34. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8499, SEQ ID NO: 9196, SEQ ID NO: 9966, SEQ ID NO: 10881, SEQ ID NO: 11516, and amino acid sequence GVS.

35. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 9969, SEQ ID NO: 10884, SEQ ID NO: 11518, and amino acid sequence TAS.

36. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8507, SEQ ID NO: 9204, SEQ ID NO: 9976, SEQ ID NO: 10975, SEQ ID NO: 11525, and amino acid sequence DDS.

37. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8508, SEQ ID NO: 9205, SEQ ID NO: 9977, SEQ ID NO: 10975, SEQ ID NO: 11526, and amino acid sequence DDT.

38. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8380, SEQ ID NO: 9084, SEQ ID NO: 9983, SEQ ID NO: 10889, SEQ ID NO: 11532, and amino acid sequence DAS.

39. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8402, SEQ ID NO: 9213, SEQ ID NO: 9987, SEQ ID NO: 11343, SEQ ID NO: 11536, and amino acid sequence AAS.

40. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8522, SEQ ID NO: 9219, SEQ ID NO: 9993, SEQ ID NO: 10894, SEQ ID NO: 11542, and amino acid sequence DDI.

41. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8389, SEQ ID NO: 9222, SEQ ID NO: 9999, SEQ ID NO: 10897, SEQ ID NO: 11547, and amino acid sequence DSS.Docket No.10644-190WO1 42. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8526, SEQ ID NO: 9223, SEQ ID NO: 10000, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS.

43. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8530, SEQ ID NO: 9227, SEQ ID NO: 10004, SEQ ID NO: 10775, SEQ ID NO: 11552, and amino acid sequence GNN.

44. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8533, SEQ ID NO: 9230, SEQ ID NO: 10007, SEQ ID NO: 12357, SEQ ID NO: 11548, and amino acid sequence DDS.

45. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8571, SEQ ID NO: 9267, SEQ ID NO: 10054, SEQ ID NO: 10925, SEQ ID NO: 11601, and amino acid sequence EVS.

46. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8573, SEQ ID NO: 9269, SEQ ID NO: 100057, SEQ ID NO: 10928, SEQ ID NO: 11604, and amino acid sequence EVS.

47. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8600, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS.

48. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8603, SEQ ID NO: 9300, SEQ ID NO: 10093, SEQ ID NO: 10956, SEQ ID NO: 11639, and amino acid sequence EVS.

49. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8618, SEQ ID NO: 9298, SEQ ID NO: 10090, SEQ ID NO: 10954, SEQ ID NO: 11636, and amino acid sequence QVS.

50. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibodyDocket No.10644-190WO1 comprises SEQ ID NO: 8624, SEQ ID NO: 9317, SEQ ID NO: 10116, SEQ ID NO: 10971, SEQ ID NO: 11661, and amino acid sequence AAS.

51. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8464, SEQ ID NO: 9199, SEQ ID NO: 10124, SEQ ID NO: 10977, SEQ ID NO: 11518, and amino acid sequence SAS.

52. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8637, SEQ ID NO: 9338, SEQ ID NO: 10140, SEQ ID NO: 10989, SEQ ID NO: 11683, and amino acid sequence GAS.

53. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8639, SEQ ID NO: 9341, SEQ ID NO: 10143, SEQ ID NO: 10992, SEQ ID NO: 11684, and amino acid sequence KAS.

54. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8624, SEQ ID NO: 9377, SEQ ID NO: 10188, SEQ ID NO: 10929, SEQ ID NO: 11722, and amino acid sequence AAS.

55. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8694, SEQ ID NO: 9402, SEQ ID NO: 10218, SEQ ID NO: 11049, SEQ ID NO: 11750, and amino acid sequence DDK.

56. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8718, SEQ ID NO: 9323, SEQ ID NO: 10251, SEQ ID NO: 11073, SEQ ID NO: 11780, and amino acid sequence YNT.

57. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8735, SEQ ID NO: 9447, SEQ ID NO: 10271, SEQ ID NO: 11086, SEQ ID NO: 11799, and amino acid sequence SAS.

58. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8538, SEQ ID NO: 9456, SEQ ID NO: 10285, SEQ ID NO: 11096,Docket No.10644-190WO1 SEQ ID NO: 11812, and amino acid sequence DDT.

59. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8756, SEQ ID NO: 9460, SEQ ID NO: 10294, SEQ ID NO: 10987, SEQ ID NO: 11820, and amino acid sequence DAS.

60. The recombinant antibody of any one of claims 1-9, wherein the recombinant antibody comprises SEQ ID NO: 8761, SEQ ID NO: 9465, SEQ ID NO: 10300, SEQ ID NO: 11103, SEQ ID NO: 11826, and amino acid sequence DDS.

61. The recombinant antibody of any one of claims 1-60, wherein the VAR2CSA antigen is expressed in a Plasmodium falciparum (P. falciparum) parasite.

62. The recombinant antibody of any one of claims 1-61, wherein the recombinant antibody is a monoclonal antibody.

63. The recombinant antibody of any one of claims 1-62, wherein the recombinant antibody is an adhesion inhibitory antibody.

64. A nucleic acid encoding the recombinant antibody of any one of claims 1-63.

65. An expression vector comprising the nucleic acid of claim 64.

66. A cell comprising the nucleic acid of claim 64 or the expression vector of claim 65.

67. A therapeutic composition comprising a recombinant antibody comprisinga lightchain variable (VL) region and a heavy chain variable (VH) region, wherein the VLand VHcomprise an antigen binding site targeting at least one VAR2CSA antigen,or a variant thereof;and a pharmaceutically acceptable carrier.

68. The therapeutic composition of claim 67, wherein the antigen binding site targets 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants.Docket No.10644-190WO169. The therapeutic composition of claim 67 or 68,wherein theVL comprises a sequenceselected from SEQ ID NO: 12306 – SEQ ID NO: 12356.

70. The therapeutic composition of any one of claims 67-69, wherein theVH comprises a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305.

71. The therapeutic composition of any one of claims 67-70, wherein theVL comprises a complementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, and an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT.

72. The therapeutic composition of any one of claims 67-71,wherein theVH comprises acomplementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 and SEQ ID NO: 8375 – SEQ ID NO: 10766.

73. The therapeutic composition of any one of claims 67-72, wherein theVL comprises: a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN,Docket No.10644-190WO1 EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254.

74. The therapeutic composition of any one of claims 67-73, wherein theVH comprises: a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766.

75. The therapeutic composition of any one of claims 67-74, wherein the VAR2CSA antigen is expressed in a Plasmodium falciparum (P. falciparum) parasite.

76. The therapeutic composition of any one of claims 67-75, wherein the recombinant antibody is a monoclonal antibody.

77. The therapeutic composition of any one of claims 67-76, wherein the recombinant antibody is an adhesion inhibitory antibody.

78. The therapeutic composition of any one of claims 67-77, further comprising an adjuvant, an additive, a preservative, or any combination thereof.Docket No.10644-190WO1 79. The therapeutic composition of any one of claims 67-78, wherein the therapeutic composition comprises a vaccine.

80. The therapeutic composition of any one of claims 67-79, wherein the pharmaceutically acceptable carrier comprises an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof.

81. A method of treating or preventing a malaria infection in a subject in need thereof, the method comprising administering a recombinant antibody or a composition comprisingthe recombinantantibody, wherein the recombinant antibody comprises a light chain variable (VL) region and a heavy chain variable (VH) region, and wherein the VL and VH comprisean antigen binding sitetargeting at least one VAR2CSA antigen, or a variant thereof.

82. The method of claim 81, wherein the antigen binding site targets 1, 2, 3, 4, 5, 6, or 7 VAR2CSA variants.

83. The method of claim 81 or 82,wherein theVL comprises a sequence selectedfrom SEQ ID NO: 12306 – SEQ ID NO: 12356.

84. The method of any one of claims 81-83, wherein theVH comprises a sequence selected from SEQ ID NO: 12255 – SEQ ID NO: 12305.

85. The method of any one of claims 81-84,wherein theVL comprises acomplementarity determining region selected from SEQ ID NO: 7483 – SEQ ID NO: 8374, SEQ ID NO: 10767 – SEQ ID NO: 12254, and an amino acid sequence comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN,Docket No.10644-190WO1 KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT.

86. The method of any one of claims 81-85, wherein theVH comprises a complementarity determining region selected from SEQ ID NO: 6527 – SEQ ID NO: 7482 and SEQ ID NO: 8375 – SEQ ID NO: 10766.

87. The method of any one of claims 81-86, wherein theVL comprises: a complementarity determining region (CDR) 1 comprising a sequence selected from SEQ ID NO: 10767- SEQ ID NO: 11343; a CDR2 comprising a sequence selected from SEQ ID NO: 11344 – SEQ ID NO: 11362 and amino acid sequences comprising GTS, EDI, DAS, EAS, AAS, GAS, GAF, GDN, EVS, LGS, KAS, YDD, DVS, YAS, WAS, EVT, RAS, KDT, DDR, EDA, SVS, KDS, ENN, EDS, DSS, KNE, QDT, YDR, DNN, DDS, EGS, ETS, LAS, RND, GVT, KDN, KLS, DND, QDN, RNN, DIS, SNN, GKN, KDR, NTN, EDN, KVS, DVT, SAS, QNT, QDS, STT, GPS, NAS, KDI, NDN, TTN, NNN, GVS, QNN, TAS, YDS, RNT, DDT, RNK, END, DVN, DTS, DDI, EDT, GIN, RTD, GNN, KNN, GGT, DAF, SDN, KNI, GAD, TTS, DVI, VAS, KIS, FET, DYN, EVN, QVS, SDS, GNS, DHN, DDD, DSF, WDS, DGS, GTN, HAS, AAA, QDK, STS, WAI, AAD, DGT, AGS, DNY, DST, DAA, DDK, DDN, AVS, YNT, QDY, GDS, DDA, EDK, DNS, YHT, QDL, KYS, ADE, DVA, ANS, GNI, TNN, ANN, DAY, DTF, GAA, NVS, AKN, DTN, WAA, ATF, YVS, DDV, DAT, EDD, GGS, WSS, ATS, QHN, LDT, QAS, NDK, LVS, SAD, SSD, RDH, ASS, LSS, NDS, ENS, KTS, DEN, NNR, GIS, SAT, ETK, STN, EGT, GVY, DVF, AAF, RNG, DVD, EDR, QDD, GSN, GRD, RNI, DIN, KSS, GEN, GAY, TAT, EVI, RDN, QEN, KAF, EDF, RVY, TMS, or GNT; and a CDR3 comprising a sequence selected from SEQ ID NO: 11363 – SEQ ID NO: 12254.Docket No.10644-190WO1 88. The method of any one of claims 81-87, wherein theVH comprises: a CDR1 comprising a sequence selected from SEQ ID NO: 8375 – SEQ ID NO: 9078; a CDR2 comprising a sequence selected from SEQ ID NO: 9079 – SEQ ID NO: 9809; and a CDR3 comprising a sequence selected from SEQ ID NO: 9810 – SEQ ID NO: 10766.

89. The method of claim 81-88, wherein the malaria infection is a placental malaria infection.

90. The method of any one of claims 81-89, wherein the malaria infection is caused by a Plasmodium falciparum (P. falciparum) infection.

91. The method of any one of claims 81-90, wherein the VAR2CSA antigen is expressed in a P. falciparum parasite.

92. The method of any one of claims 81-91, wherein the recombinant antibody is a monoclonal antibody.

93. The method of any one of claims 81-92, wherein the recombinant antibody is an adhesion inhibitory antibody.

94. The method of any one of claims 81-93, further comprising an adjuvant, an additive, a preservative, or any combination thereof.

95. The method of any one of claims 81-94, wherein the composition comprises a vaccine.

96. The method of any one of claims 81-95, wherein the composition comprises an excipient, a diluent, a salt, a buffer, a stabilizer, a lipid, an emulsion, a nanoparticle, or any combination thereof.

97. The method of any one of claims 81-96, wherein the recombinant antibody preventsDocket No.10644-190WO1 or inhibits the VAR2CSA antigen from binding to a chondroitin sulphate A (CSA) receptor.

98. The method of claim 97, wherein the CSA receptor is expressed in the subject.

Images